Higher plasma C-reactive protein and lower plasma adiponectin are associated with increased carotid artery intima-media thickness in patients with impaired glucose regulation

1. The prevention or delay of type 2 diabetes. Diabetes Care. 2002; 25:742-9.10.2337/diacare.25.4.74211919135Open DOISearch in Google Scholar

2. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30:753-9.10.2337/dc07-992017327355Open DOISearch in Google Scholar

3. Richard EP, Matfin G. Pre-diabetes: Clinical Relevence and Therapeutic Approach. Br J Diabetes Vasc Dis. 2007; 7:120-9.10.1177/14746514070070030401Open DOISearch in Google Scholar

4. Group TDS. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003; 26:61-9.10.2337/diacare.26.1.6112502659Search in Google Scholar

5. Qiao Q, Hu G, Tuomilehto J, Nakagami T, Balkau B, Borch-Johnsen K, et al. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care. 2003; 26:1770-80.10.2337/diacare.26.6.177012766108Search in Google Scholar

6. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ). 2005; 128:1-11.Search in Google Scholar

7. Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol. 2005; 5:129-34.10.1016/j.coph.2005.01.00115780820Open DOISearch in Google Scholar

8. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005; 6:13-21.10.1111/j.1467-789X.2005.00159.x15655035Open DOISearch in Google Scholar

9. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003; 52:1779-85.10.2337/diabetes.52.7.177912829646Open DOISearch in Google Scholar

10. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004; 27:2450-7.10.2337/diacare.27.10.245015451915Open DOISearch in Google Scholar

11. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999; 22:233-40.10.2337/diacare.22.2.23310333939Search in Google Scholar

12. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002; 25:829-34.10.2337/diacare.25.5.829Open DOISearch in Google Scholar

13. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-thanoptimum blood glucose concentration: comparative risk assessment. Lancet. 2006; 368:1651-9.10.1016/S0140-6736(06)69700-6Open DOISearch in Google Scholar

14. Williams DR, Wareham NJ, Brown DC, Byrne CD, Clark PM, Cox BD, et al. Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabet Med. 1995; 12:30-5.10.1111/j.1464-5491.1995.tb02058.xOpen DOISearch in Google Scholar

15. Claudi T, Midthjell K, Holmen J, Fougner K, Kruger O, Wiseth R. Cardiovascular disease and risk factors in persons with type 2 diabetes diagnosed in a large population screening: the Nord-Trondelag Diabetes Study, Norway. J Intern Med. 2000; 248:492-500.10.1046/j.1365-2796.2000.00759.xOpen DOISearch in Google Scholar

16. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980; 1:1373-6.10.1016/S0140-6736(80)92651-3Open DOISearch in Google Scholar

17. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999; 340:14-22.10.1056/NEJM1999010734001039878640Open DOISearch in Google Scholar

18. Pujia A, Gnasso A, Irace C, Colonna A, Mattioli PL. Common carotid arterial wall thickness in NIDDM subjects. Diabetes Care. 1994; 17:1330-6.10.2337/diacare.17.11.13307821175Open DOISearch in Google Scholar

19. Bonora E, Tessari R, Micciolo R, Zenere M, Targher G, Padovani R,et al. Intimal-medial thickness of the carotid artery in nondiabetic and NIDDM patients. Relationship with insulin resistance. Diabetes Care. 1997; 20:627-31.10.2337/diacare.20.4.6279096992Open DOISearch in Google Scholar

20. Goff DC Jr, D’Agostino RB, Haffner SM, Saad MF, Wagenknecht LE. Lipoprotein concentrations and carotid atherosclerosis by diabetes status: results from the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2000; 23:1006-11.10.2337/diacare.23.7.100610895855Open DOISearch in Google Scholar

21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412-9.10.1007/BF002808833899825Open DOISearch in Google Scholar

22. Aydin Y, Berker D, Ustun I, Gul K, Erden G, Kutlucan A, et al. Evaluation of carotid intima media thickness in impaired fasting glucose and impaired glucose tolerance. Minerva Endocrinol. 2011; 36:171-9.Search in Google Scholar

23. Brohall G, Oden A, Fagerberg B. Carotid artery intimamedia thickness in patients with type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med. 2006; 23:609-16.10.1111/j.1464-5491.2005.01725.x16759301Open DOISearch in Google Scholar

24. Karasik A: Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum. Ann Med. 2005; 37:250-8.10.1080/0785389051003736516019723Open DOISearch in Google Scholar

25. Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant. 2009; 24:1876-83.10.1093/ndt/gfn77019164322Search in Google Scholar

26. Gokulakrishnan K, Indulekha K, Ganesan S, Anuradha S, Mohan V. Adiponectin and carotid intimal medial thickness in subjects with and without glucose intolerance (CURES-82). Diabetes Technol Ther. 2010; 12:109-15.10.1089/dia.2009.010020105040Open DOISearch in Google Scholar

27. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002; 51:2796-803.10.2337/diabetes.51.9.279612196473Open DOISearch in Google Scholar

28. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A, et al. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia. 2003; 46:1211-9.10.1007/s00125-003-1169-612879253Open DOISearch in Google Scholar

29. Nilsson PM, Engström G, Hedblad B, Frystyk J, Persson MM, Berglund G, et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol. 2006; 26:2758-62.10.1161/01.ATV.0000249638.01416.4b17038635Open DOISearch in Google Scholar

30. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286:327-34.10.1001/jama.286.3.32711466099Search in Google Scholar

31. Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH, et al. Genetic variation, Creactive protein levels, and incidence of diabetes. Diabetes. 2007; 56:872-8.10.2337/db06-092217327459Open DOISearch in Google Scholar

32. Shahid HS, Kurdi MI, Zohair AA. Serum highsensitivity C-reactive protein and lipoprotein(a) levels: a comparison between diabetic and non-diabetic patients with coronary artery disease. Med J Malaysia. 2011; 66:113-6.Search in Google Scholar